Quantum BioPharma Ltd. (NASDAQ: QNTM) has secured U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, allowing the company to proceed with Phase 2 clinical testing of its multiple sclerosis candidate. The milestone marks a critical step for a drug that takes a fundamentally different approach to treating MS, a chronic disease in which the immune system attacks the protective myelin sheath around nerve fibers, leading to progressive disability.
Unlike most existing MS therapies that modulate or suppress the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage. This mechanism could offer a complementary or alternative strategy for patients who do not respond adequately to current treatments. The planned Phase 2 study will be randomized, double-blind, and placebo-controlled, evaluating the drug's efficacy, safety, and tolerability in patients with MS. Researchers will assess clinical symptoms as well as changes visible through brain imaging, providing objective measures of the drug's impact on disease progression.
Lucid-MS previously completed Phase 1 trials in healthy volunteers, where the company reported a favorable safety profile and good tolerability. Those results support advancing the compound into a larger patient population. If successful, Lucid-MS could become the first therapy in its class to directly target myelin degradation, potentially slowing or reversing disability in MS patients. The global MS market is substantial, with hundreds of thousands of patients seeking more effective and better-tolerated options. Quantum BioPharma's progress therefore matters not only for its shareholders but also for the broader MS community, which has long awaited treatments that address the underlying cause of nerve damage rather than just the immune response.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.48% ownership stake as of June 30, 2026. The agreement includes royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For investors tracking Quantum BioPharma, the latest news and updates are available in the company's newsroom at https://ibn.fm/QNTM. The full article on the FDA clearance can be accessed at https://ibn.fm/g5EXE. BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
